Cite
The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice.
MLA
Choi, Jungmi, et al. “The SGLT2 Inhibitor Empagliflozin Improves Cardiac Energy Status via Mitochondrial ATP Production in Diabetic Mice.” Communications Biology, vol. 6, no. 1, Mar. 2023, pp. 1–9. EBSCOhost, https://doi.org/10.1038/s42003-023-04663-y.
APA
Choi, J., Matoba, N., Setoyama, D., Watanabe, D., Ohnishi, Y., Yasui, R., Kitai, Y., Oomachi, A., Kotobuki, Y., Nishiya, Y., Pieper, M. P., Imamura, H., Yanagita, M., & Yamamoto, M. (2023). The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice. Communications Biology, 6(1), 1–9. https://doi.org/10.1038/s42003-023-04663-y
Chicago
Choi, Jungmi, Naoki Matoba, Daiki Setoyama, Daiki Watanabe, Yuichiro Ohnishi, Ryuto Yasui, Yuichirou Kitai, et al. 2023. “The SGLT2 Inhibitor Empagliflozin Improves Cardiac Energy Status via Mitochondrial ATP Production in Diabetic Mice.” Communications Biology 6 (1): 1–9. doi:10.1038/s42003-023-04663-y.